Roivant Sciences (ROIV) Liabilities and Shareholders Equity (2021 - 2026)

Roivant Sciences (ROIV) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $5.7 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 5.0% year-over-year to $5.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.0 billion (down 12.13% YoY) and the FY2026 annual result came in at $5.7 billion, up 5.0% from the prior year.
• Liabilities and Shareholders Equity grew to $5.7 billion in Q1 2026, from $5.2 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $7.3 billion in Q4 2023 to a low of $2.1 billion in Q3 2023.
• A 5-year average of $4.5 billion and a median of $5.1 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slipped 28.6% — and 2023, when it soared 231.95%.
• Tracing ROIV's Liabilities and Shareholders Equity over 5 years: stood at $2.2 billion in 2022, then soared by 231.95% to $7.3 billion in 2023, then fell by 20.79% to $5.8 billion in 2024, then fell by 9.79% to $5.2 billion in 2025, then rose by 9.25% to $5.7 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $5.7 billion (Q1 2026), $5.2 billion (Q4 2025), and $5.1 billion (Q3 2025), per Business Quant data.